

Mark B Geyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/119110/publications.pdf>

Version: 2024-02-01

53
papers

2,451
citations

304743

22
h-index

223800

46
g-index

53
all docs

53
docs citations

53
times ranked

4096
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab. <i>Blood Advances</i> , 2022, 6, 1432-1443.	5.2	13
2	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2022, 386, 735-743.	27.0	87
3	Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 176-184.	1.3	7
4	Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. <i>Blood</i> , 2021, 138, 531-543.	1.4	42
5	Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. <i>Leukemia and Lymphoma</i> , 2021, 62, 1940-1948.	1.3	7
6	Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 377-387.	4.1	17
7	Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 2086-2094.	3.5	24
8	A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. <i>Blood</i> , 2021, 138, 2828-2837.	1.4	65
9	Abstract 10135: Cardiotoxicity and Mortality in Chimeric Antigen Receptor T Cell Therapy Recipients. <i>Circulation</i> , 2021, 144, .	1.6	2
10	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	1.4	248
11	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	5.2	55
12	<i>FGFR1</i> Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute Leukemia. <i>JCO Precision Oncology</i> , 2020, 4, 937-943.	3.0	2
13	Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naïve acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2497-2501.	1.3	1
14	Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib. <i>Blood</i> , 2020, 136, 8-9.	1.4	4
15	Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy As Consolidation and Maintenance Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction. <i>Blood</i> , 2020, 136, 45-45.	1.4	0
16	The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 226-235.	2.4	5
17	Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. <i>JCI Insight</i> , 2019, 4, .	5.0	71
18	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. <i>Cancer Immunology Research</i> , 2019, 7, 1047-1053.	3.4	59

#	ARTICLE	IF	CITATIONS
19	Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2019, 79, 27-33.	0.8	54
20	BRAF in the cross-hairs. <i>Expert Review of Hematology</i> , 2019, 12, 183-193.	2.2	0
21	Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features. <i>Leukemia Research Reports</i> , 2019, 12, 100186.	0.4	1
22	First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval. <i>Clinical Cancer Research</i> , 2019, 25, 1133-1135.	7.0	18
23	Chimeric Antigen Receptor-T Cells for Leukemias in Adults: Methods, Data and Challenges. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 75-92.	0.0	0
24	Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 5079-5079.	1.4	6
25	Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients. <i>Blood</i> , 2019, 134, 1758-1758.	1.4	1
26	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4019-4019.	1.4	20
27	Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss. <i>Blood</i> , 2019, 134, 3888-3888.	1.4	2
28	Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients. <i>Blood</i> , 2019, 134, 3887-3887.	1.4	1
29	Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission. <i>Leukemia and Lymphoma</i> , 2018, 59, 269-271.	1.3	0
30	Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. <i>Leukemia and Lymphoma</i> , 2018, 59, 1717-1721.	1.3	6
31	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. <i>Molecular Therapy</i> , 2018, 26, 1896-1905.	8.2	65
32	Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. <i>Blood</i> , 2017, 129, 1878-1881.	1.4	77
33	CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. <i>Blood</i> , 2016, 127, 3312-3320.	1.4	346
34	Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. <i>Cytotherapy</i> , 2016, 18, 1393-1409.	0.7	79
35	Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Pediatrics</i> , 2015, 167, 765-769.e1.	1.8	25
36	Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. <i>Bone Marrow Transplantation</i> , 2014, 49, 913-920.	2.4	87

#	ARTICLE	IF	CITATIONS
37	Enhanced Survival During Experimental <i>Listeria monocytogenes</i> Sepsis in Neonatal Mice Prophylactically Treated With Th1 and Macrophage Immunoregulatory Cytokines and Mediators. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, e330-e337.	2.0	2
38	A Comparison of Bronchoalveolar Lavage versus Lung Biopsy in Pediatric Recipients after Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1229-1237.	2.0	29
39	Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1289-1294.	1.5	11
40	Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia</i> , 2013, 27, 1174-1177.	7.2	137
41	Rituximab pharmacokinetics in children and adolescents with <i>de novo</i> intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. <i>British Journal of Haematology</i> , 2013, 162, 678-683.	2.5	31
42	Busulfan, Fludarabine, and Alemtuzumab Conditioning and Unrelated Cord Blood Transplantation in Children with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 676-677.	2.0	45
43	The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients. <i>Bone Marrow Transplantation</i> , 2013, 48, 19-25.	2.4	6
44	Rituximab pharmacokinetics in children and adolescents with <i>de novo</i> intermediate and advanced mature B-cell lymphoma/leukemia: A Children's Oncology Group (COG) report. <i>Journal of Clinical Oncology</i> , 2013, 31, 3055-3055.	1.6	0
45	Epidemiology of Hematological Malignancies of Children, Adolescents, and Young Adults. , 2012, , 1-13.		2
46	Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortality. <i>British Journal of Haematology</i> , 2012, 156, 99-108.	2.5	25
47	Starry sky. <i>British Journal of Haematology</i> , 2012, 156, 783-783.	2.5	1
48	T cell depletion utilizing $CD^{34}+$ stem cell selection and $CD^{3}+$ addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients. <i>British Journal of Haematology</i> , 2012, 157, 205-219.	2.5	35
49	Low day 100 transplant-related mortality (TRM) and relapse rate following clofarabine (CLO) in combination with cytarabine, total body irradiation (TBI), and allogeneic stem cell transplantation (AlloSCT) in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 6537-6537.	1.6	0
50	A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning <i>versus</i> reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. <i>British Journal of Haematology</i> , 2011, 155, 218-234.	2.5	52
51	Cord blood transplantation and stem cell regenerative potential. <i>Experimental Hematology</i> , 2011, 39, 393-412.	0.4	53
52	Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia. <i>Blood</i> , 2010, 116, 36-36.	1.4	2
53	IgH class switching and translocations use a robust non-classical end-joining pathway. <i>Nature</i> , 2007, 449, 478-482.	27.8	523